CSPC Megalith Biopharmaceutical Co.,Ltd.
21
6
7
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
4.8%
1 terminated/withdrawn out of 21 trials
0.0%
-86.5% vs industry average
33%
7 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Role: lead
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
Role: lead
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
Role: lead
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Role: lead
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
Role: lead
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
Role: lead
SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma
Role: lead
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Role: lead
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
Role: lead
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
Role: lead
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
Role: lead
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Role: lead
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Role: lead
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
Role: lead
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Role: lead
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
Role: lead
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
Role: lead
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
Role: lead
Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
Role: lead
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
Role: lead